A study testing whether a new weekly shot from University of Texas Southwestern Medical Center, tirzepatide, can help with weight.

Who can join: Adults 18 to 65, have obesity, BMI 27+.
What you take: tirzepatide, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.
How long it lasts: The full study runs about 3.6 years; your own time in it is usually shorter.
What you get: The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.

Phase Phase 2Sponsor University of Texas Southwestern Medical CenterDrug tirzepatideClass GLP-1/GIPSites 1 USEnrollment target 45

What this study is for

Primary condition: Obesity. Also studied in: Methamphetamine Use Disorder, Cocaine Use Disorder, Stimulant Use Disorders.

Full scientific study title: An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder.

Who can join

Age18 to 65SexAnyBMI27 or higher

Adults 18 to 65, have obesity, BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Be 18 to 65 years of age, inclusive.
Be able to provide informed consent and ask relevant questions.
Stated willingness to comply with all study procedures and availability for the duration of the study.
Be willing to adhere to the study medication regimen
Meet DSM-5 criteria for moderate or severe methamphetamine, cocaine or prescription stimulant use disorder.

Key exclusion criteria

Current or recent use (within 3 months prior to consent) of other tirzepatide-containing products or any other GLP-1 receptor agonist
Current or recent use (within 30 days) of sulfonylureas, other concomitantly administered insulin secretagogue, or insulin
Current or recent use (within 3 months prior to consent) of other weight loss agents
Weight loss surgery within 12 months prior to consent
Current eating disorder per clinician evaluation

Where this study is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

Texas1 site

UT Southwestern Medical Center
Dallas, Texas
Virgilio Garza, B.S.6823768622Virgilio.Garza@UTSouthwestern.edu

Follow this trial

We email you if NCT07693608 changes status, adds new sites in your state, or if a similar trial opens for the same condition. No spam, opt out any time.

Timeline

Started enrolling: 2026-08-01. Expected completion: 2030-03-01. Last updated on ClinicalTrials.gov: 2026-07-09.

Official source

We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact

Why you can trust GLP ChartSame scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.